Shares of HLS Therapeutics Inc. (TSE:HLS – Get Free Report) traded down 0.8% during trading on Wednesday . The company traded as low as C$3.73 and last traded at C$3.75. 17,200 shares changed hands during trading, a decline of 37% from the average daily volume of 27,381 shares. The stock had previously closed at C$3.78.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Raymond James Financial upgraded shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from C$7.00 to C$8.00 in a research note on Friday, August 14th. Canaccord Genuity Group upgraded HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Strong Buy” and an average target price of C$8.00.
Read Our Latest Stock Analysis on HLS Therapeutics
HLS Therapeutics Price Performance
HLS Therapeutics (TSE:HLS – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%.The firm had revenue of C$14.67 million during the quarter. During the same period in the previous year, the firm posted ($0.09) earnings per share. Research analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.
See Also
- Five stocks we like better than HLS Therapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
